Geospace Technologies (Nasdaq: GEOS ) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q2), Geospace Technologies whiffed on revenues and whiffed on earnings per share.
Compared to the prior-year quarter, revenue increased significantly. GAAP earnings per share increased significantly.
Margins grew across the board.
Revenue details
Geospace Technologies notched revenue of $76.4 million. The seven analysts polled by S&P Capital IQ anticipated a top line of $86.2 million on the same basis. GAAP reported sales were 36% higher than the prior-year quarter's $56.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
EPS came in at $1.30. The seven earnings estimates compiled by S&P Capital IQ forecast $1.71 per share. GAAP EPS of $1.30 for Q2 were 46% higher than the prior-year quarter's $0.89 per share.
NanoViricides, Inc., incorporated on April 1, 2005, is a development-stage company. The Company is a nano-biopharmaceutical (nanomedicine) company whose business goals are to discover, develop and commercialize therapeutics to advance the care of patients suffering from life-threatening viral infections. The Company has several drugs in various stages of early development. The Company�� drugs are based on several patents, patent applications, provisional patent applications, and other property held by TheraCour Pharma, Inc. (TheraCou), to which the Company has exclusive licenses in perpetuity for the treatment of human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Influenza including Asian Bird Flu Virus (INF), Herpes Simplex Virus (HSV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), and Rabies. As of June 30, 2012, the Company had six drug development programs: Oral FluCideTM, against all Influenzas; a Piggy-back version of Flucide for hospitalized patients; nanoviricide eye drops against adenoviral EKC and herpes keratitis; HIVCide - I against HIV/AIDS; HerpeCide - I skin cream formulation for herpes cold sores and genital warts, and DengueCide, a broad spectrum nanoviricide designed to attack all types of dengue viruses and expected to be effective in the Severe Dengue Disease syndromes including Dengue Hemorrhagic Fever (DHS) and Dengue Shock Syndrome (DSS). As of June 30, 2012, it had engaged in organizational activities, sourcing compounds and materials, developing novel compounds and nanomaterials, and experimentation with studies on cell cultures and animals. In September 2011, NanoViricides Inc's Inno-Haven LLC acquired a light industrial building.
The Company's product development programs are divided into three sectors: commercially important diseases, neglected tropical diseases (NTD��) and biosecurity/biodefense, and advanced technologies. The Company has collaborations with KARD Scientific, Inc., MA. and Southern Research Institute, AL for influenza viruse! s; National (Central) Institute of Hygiene and Epidemiology (NIHE) (Vietnam), for H5N1 avian flu; The Long Island Jewish Medical System, Feinstein Institute of Medical Research (LIJMS), NY and TheVac, LLC. for viral diseases of the eye (adenoviruses, herpesviruses - epidemic kerato-conjunctivitis (EKC), Herpes Keratitis); TheVac, LLC and Northeastern Ohio Medical University (NEOMED) for herpes virus infections; University of California at Berkeley for dengue hemorrhagic fever viruses; Center for Disease Control and Prevention (CDC) and National (Central) Institute of Hygiene and Epidemiology for rabies virus. The Company has developed lead drug candidates against a number of viral diseases.
The Company had consolidated all of its influenza drug programs into a single pan-influenza FluCide program. It is developing a single drug for all influenzas, whether pandemic, epidemic, seasonal, novel, emerging, human, swine, or avian. It is developing a nanoviricide against adenoviral EKC. The nanoviricide eye drug candidate is formulated as simple eye drops. It is developing an anti-HSV nanoviricide skin cream formulation for direct application to the lesions. It has designed the anti-HIV nanoviricides using rational drug design principles. The ligands it has designed in the case of HIV-1 are thought to be broadly neutralizing. In-silico modeling indicates that its ligands dock to the conserved CD4 binding site of gp120 of HIV-1. The Company is working on developing anti-Dengue therapeutics. Dengue is an important NTD. Its RabiCide program has resulted in candidates that have enabled survival of 20% to 30% of infected animals after disease has set in, using a particular animal model.
The Company competes with Roche, Glaxo SmithKline, BioCryst Pharmaceuticals, Inc., Gilead, Bristol-Myers Squibb Company (BMS), Roche, Boehringer Ingelheim, Merck & Co., Inc. (Merck), Valeant, Schering, Pharmassett, Vertex, Intermune, Achillion and Novartis.
Advisors' Opinion: - [By Roberto Pedone]
One under-$10 nano-biopharmaceutical player that's starting to trend within range of triggering a big breakout trade is Nanoviricides (NNVC), which engages in the discovery, development and commercialization of anti-viral therapeutics primarily in the U.S. This stock has been ripping to the upside so far in 2013, with share up big by 198%.
If you take a look at the chart for Nanoviricides, you'll notice that this stock has recently formed a double bottom chart pattern at $4.55 to $4.52 a share. Following that bottom, shares of NNVC have now started to uptrend and move within range of triggering a big breakout trade. That trade will hit if NNVC manages to take out the upper-end of its recent sideways trading chart pattern, which has seen NNVC trend between $4.55 and $5.74 a share.
Traders should now look for long-biased trades in NNVC if it manages to break out above some near-term overhead resistance levels at Friday's high of $4.94 a share to its 50-day moving average of $5.28 a share, and then once it takes out some more key overhead resistance levels at $5.72 to $5.74 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 234,994 shares. If that breakout triggers soon, then NNVC will set up to re-test or possibly take out its next major overhead resistance levels at $6.50 to its 52-week high at $7.59 a share.
Traders can look to buy NNVC off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $4.55 to $4.52 a share. One can also buy NNVC off strength once it starts to clear those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Top 10 Tech Stocks To Watch Right Now: TIBCO Software Inc.(TIBX)
TIBCO Software Inc. provides middleware and infrastructure software worldwide. It offers products in the areas of service-oriented architecture (SOA) and core infrastructure; business optimization; and process automation and collaboration. Its SOA and core infrastructure product line helps organizations integrate their disparate systems and move towards flexible infrastructure comprised of services or discrete data components that can be assembled, orchestrated, and reused; and enables the creation, management, and virtualization of heterogeneous services. The company?s business optimization product portfolio assists organizations analyze data to create information and deliver it to employees, customers, and partners; and employees perform their jobs, and customers get information, as well as helps managers identify and analyze problems and opportunities. Its process automation and collaboration software helps organizations coordinate manual and automated process flows th at span their business and enables employees to collaborate in real-time using social media; and coordinate the human and electronic resources inside a business and its network of customers and partners. The company also provides professional services, which include consulting services that comprise systems planning and design, installation, and systems integration; maintenance and support; training; and hosted services. It serves various industries, such as financial services, telecommunications, government, energy, life sciences, insurance, logistics, manufacturing, retail, and transportation. The company sells its products through direct sales force, as well as through software vendors, resellers, and systems integrators. TIBCO Software Inc. was founded in 1985 and is headquartered in Palo Alto, California.
Advisors' Opinion: Top 10 Tech Stocks To Watch Right Now: Shanda Games Ltd (GAME)
Shanda Games Limited (Shanda Games), incorporated on June 12, 2008, is engaged in the development and operation of online games and related businesses in the People�� Republic of China. Some of its online games are also Web games, which the Company categorizes as either massively multiplayer online role-playing games (MMORPGs) or advanced casual games, rather than as a separate category of online games. As of February 29, 2012, Shanda Games operated 35 online games. Its game player base, which consisted of 20.4 million average monthly active users and 4.5 million average monthly paying users for the three-month period ended December 31, 2011. In April 2011, the Company acquired a 51.85% interest in a game operating company, which provides services in East Asia.
As of December 31, 2011, the Company owned 149 software copyrights. As of December 31, 2011, it owned or licensed 53 trademarks. As of December 31, 2011, it owned or licensed 329 registered domain names, including its official Website and domain names registered in connection with each of the games the Company offers. As of December 31, 2011, it had 17 patent applications pending with the State Intellectual Property Office of China. The Company operates MMORPGs, advanced casual games and Web games in China. Its MMORPGs are action adventure-based and draw upon themes, such as martial arts adventure, fantasy, strategy and historical events. The Company develops and sources an array of game content through multiple channels, including in-house development, licensing, investment and acquisition, and joint operation. Through these channels, it has built a diversified game portfolio and a game pipeline.
The Company licenses games from international and domestic developers. As of February 29, 2012, 13 of its 35 online games were licensed from third-party developers, including Mir II. It invests in independent game development and operating studios identified by 18 Capital. The Company acquire intellectual property rights t! o online games; equity rights in online game development and operating studios, or an option to acquire equity interests in online game development and operating studios in the future.
The Company operates its business in People's Republic of China, through its wholly owned subsidiaries, which consist of Shengqu Information Technology (Shanghai) Co., Ltd. (Shengqu), Shengji Information Technology (Shanghai) Co., Ltd. (Shengji), Lansha Information Technology (Shanghai) Co., Ltd. (Lansha) and Kuyin Software (Shanghai) Co., Ltd (Kuyin); its variable interest entities and their subsidiaries (VIEs), which consist of Shanghai Hongli Digital Technology Co., Ltd. (Shanghai Hongli) and Shanghai Shulong Technology Development Co., Ltd. (Shanghai Shulong) and their wholly owned subsidiaries, Shanghai Shulong Computer Technology Co., Ltd. (Shulong Computer), Nanjing Shulong Computer Technology Co., Ltd. (Nanjing Shulong), Chengdu Youji Technology Co., Ltd. (Chengdu Youji), Tianjin Youji Technology Co., Ltd. (Tianjin Youji), Chengdu Aurora Technology Development Co., Ltd. (Chengdu Aurora), and Chengdu Simo Technology Co., Ltd. (Chengdu Simo).
The Company competes with Tencent Holdings Limited, NetEase.com, Changyou.com Limited, Perfect World Co., Ltd., Giant Interactive, Kingsoft Corporation Limited, KongZhong Corporation, NetDragon Websoft Inc., Nineyou International Limited, The9 Limited, Activision Blizzard, Inc., Electronic Arts Inc., Zynga Inc., NCSoft Corporation, and Nexon Corporation.
Advisors' Opinion: - [By Kevin Chen]
On the heels of a resignation, Shanda Games� (NASDAQ: GAME ) has appointed a new member to its board of directors.
The company announced Wednesday that due to personal reasons, Guoxing Jiang had resigned from his spot on the board and also the Audit Committee. Replacing him will be Yong Gui. In the company's press release, Chairman Tianqiao Chen said of the new choice:
- [By Kevin Chen]
Two companies that seem on an unstoppable path of profits are Giant Interactive� (NYSE: GA ) and NetEase (NASDAQ: NTES ) .�Meanwhile, Shanda Games� (NASDAQ: GAME ) and Perfect World� (NASDAQ: PWRD ) haven't done as well.
- [By Eric Volkman]
Shanda Games� (NASDAQ: GAME ) saw a decline in bottom line for its Q3, but still beat analyst estimates. The China-based company posted revenue of 1.12 billion yuan�($183 million), modestly higher than the 1.09 billion yuan�($178 million)�in the same period the previous year. Attributable net income came in at just under 399 million yuan ($65 million;�$0.24 per diluted American depositary share), compared with Q3 2012's 405 million yuan ($66 million;�$0.24).
- [By Evan Niu, CFA]
What: Shares of Shanda Games (NASDAQ: GAME ) have popped today by as much as 11% after the game maker launched a new title with early success.
Top 10 Tech Stocks To Watch Right Now: Redpoint Bio Corp (RPBC)
Redpoint Bio Corporation (Redpoint), incorporated in August 1995, is a development-stage biotechnology company. The Company leverages discoveries in the molecular biology of taste to discover and develop taste modulators for the food and beverage industries. Its food and beverage program has been focused on identifying flavor modifiers that improve the taste of ingredients. In June 2009, the Company announced that it had identified an all-natural sweetness enhancer, RP44. RP44 is Reb-C (rebaudioside C), a component of the stevia plant.
Sweetness Enhancer Program
Redpoint announced that it had identified RP44, an all-natural sweetness enhancer, in June 2009. In January 2010, it disclosed that RP44 is Reb-C (rebaudioside C), a component of the stevia plant. RP44 is derived from material found in the side stream of the Reb A production process. A purified component of stevia known as Reb A has received regulatory approval in the United States. Unlike Reb A, RP44 has a low intrinsic level of sweetness and therefore is not useful as a sweetener.
Diabetes and Obesity Drug Discovery Program
The Company�� initial programs focused on the modulation of the TRPm5 ion channel, a signaling element in taste sensation, in order to discover compounds that modulate the taste of food and beverage products. Redpoint initiated a program designed to leverage the research it had already conducted on the discovery of modulators of the TRPm5 ion channel to further explore opportunities for the discovery of diabetes or obesity therapeutics. TRPm5 modulators discovered at Redpoint have been shown to elicit the secretion of hormones known to play roles in metabolism in relevant model systems.
The Company competes with International Flavors & Fragrances Inc., Givaudan SA, Symrise, Firmenich, Senomyx, PureCircle Ltd, GLG Life Tech Corporation, Eli Lilly and Company, Amylin Pharmaceuticals, Merck & Co., Inc., Metabolex, Inc., OSI Pharmaceuticals, GlaxoSmithKline! , Arena Pharmaceuticals, Inc. and Johnson & Johnson.
Advisors' Opinion: - [By Peter Graham]
Small cap stocks Greenfield Farms Food Inc (OTCMKTS: GRAS), International Stem Cell Corp (OTCMKTS: ISCO) and Redpoint Bio Corporation (OTCMKTS: RPBC) have all been getting some extra attention lately in various investment newsletters. However, none of these small cap stocks appear to have been the subject or paid promotions or investor relations activities. So does that make any of them good bets for traders and investors alike? Here is a quick look and a reality check:
Top 10 Tech Stocks To Watch Right Now: GSI Group Inc.(GSIG)
GSI Group Inc. designs, develops, manufactures, and sells laser-based solutions, laser scanning devices, and precision motion and optical control technologies worldwide. The company?s Laser Products segment provides lasers and laser-based systems for photonics-based applications, such as cutting, welding, marking, engraving, micro-machining, and scientific research. Its Precision Motion and Technologies segment designs, manufactures, and markets air bearing spindles, encoders, thermal printers, laser scanning devices, and light and color measurement systems to original equipment manufacturers. The company?s Semiconductor Systems segment offers laser based production systems for semiconductor, microelectronics, and electronics manufacturing. This segment?s products comprise WaferRepair for dynamic random access memory, flash memory chips, and LCDs; WaferMark for silicon suppliers and integrated circuit factories; and WaferTrim and Circuit Trim for analog and mixed signal sensor and chip resistor devices, as well as for resistor devices. The company sells its products primarily through direct sales force, resellers, distributors, and system integrators. It serves industrial, electronics, automotive, medical, packaging, aerospace, scientific, semiconductor, lighting, military, and motion picture markets. The company was formerly known as GSI Lumonics Inc. and changed its name to GSI Group Inc. in 2005. GSI Group Inc. was founded in 1970 and is based in Bedford, Massachusetts.
Advisors' Opinion: Top 10 Tech Stocks To Watch Right Now: Pegasystems Inc.(PEGA)
Pegasystems Inc. develops, markets, licenses, and supports software to automate business processes primarily in the United States, the United Kingdom, and rest of Europe. The company offers PegaRULES Process Commander, which provides a platform to build, deploy, and change enterprise applications; purpose or industry-specific solution frameworks that enable organizations to implement new customer-facing practices and processes, and provide customized or specialized processing to meet the needs of different customers, departments, geographies, or regulatory requirements; and Pega customer relationship management software to automate customer service inquiries and marketing, and apply analytics to predict and adapt customer service processes. It also offers Pega decision management products, which include Pega Decision Strategy Manager and Next-Best-Action Advisor that support decision-making for offer management, risk, and other marketing and customer management solutions; and Pega Cloud, which enables customers to create and/or run Pega applications using an Internet-based infrastructure. In addition, the company provides implementation, consulting, training, and technical support services to its customers. The company markets its software and services primarily through its direct sales force to financial services organizations, healthcare organizations, insurance companies, communications and media organizations, and government agencies. Pegasystems Inc. was founded in 1983 and is headquartered in Cambridge, Massachusetts.
Advisors' Opinion: - [By Garrett Cook]
Technology shares rose by just 0.05 percent on Wednesday. Top losers in the sector included Pegasystems (NASDAQ: PEGA), down 13.4 percent, and HomeAway (NASDAQ: AWAY), off 11 percent.
- [By Patricio Kehoe]
The firm is currently Zacks Rank # 3 - Hold, and it also has a longer-term recommendation of ��utperfom�� For investors looking for a Zacks Rank # 1 ��Strong Buy, Dealertrack Technologies Inc (TRAK), Open Text Corporation (OTEX), Pegasystems Inc. (PEGA) Solera Holdings (SLH) or Ultimate Software Group Inc. (ULTI) could be the options.
Top 10 Tech Stocks To Watch Right Now: NeoPhotonics Corp (NPTN)
NeoPhotonics Corporation, incorporated on October 31, 1996, is a designer and manufacturer of photonic integrated circuit (PIC)-based modules and subsystems for bandwidth-intensive, high-speed communications networks. The Company has a portfolio of over 300 products, including products that enable data transmission at 10 gigabytes per second, 40 gigabytes per second and 100 gigabytes per second, agility products, such as reconfigurable optical add/drop multiplexers (ROADMs) that allocate bandwidth to adjust for volatile traffic patterns, and access products that provide high-bandwidth connections to more devices and people over fixed and wireless networks. In October 2011, the Company acquired Santur Corporation. In June 2013, it announced first shipments of optical transceiver modules out of its new, high capacity factory in Dongguan, Guangdong Province, China.
The Company�� products are categorized in 34 product families. The Company sells its products to the network equipment vendors globally, including ADVA AG Optical Networking Ltd., Alcatel-Lucent SA, Ciena Corporation (including its recent acquisition of Nortel�� Metro Ethernet Networks business), Cisco Systems, Inc., FiberHome Technologies Group, ECI Telecom Ltd., Telefonaktiebolaget LM Ericsson, Fujitsu Limited, Harmonic, Inc., Huawei Technologies Co., Ltd., Mitsubishi Electric Corporation, NEC Corporation, Nokia Siemens Networks B.V. and ZTE Corporation.
The Company competes with Finisar Corporation, JDS Uniphase Corporation, MRV Communications, Inc., NTT Electronics Corporation and Sumitomo Electric Device Innovations, Inc.
Advisors' Opinion: - [By Anders Bylund]
Close competitor NeoPhotonics (NYSE: NPTN ) soared 15% higher. Larger rival JDS Uniphase (NASDAQ: JDSU ) jumped 7.9% to become the fastest gainer on the S&P 500. If Ciena can beat its own expectations in selling Internet backbone equipment to a bevy of major telecoms, its chief rivals must eventually follow suit. JDS is only one month removed from its latest quarterly report, which sent shares diving 7% overnight (but all was forgiven a week later). NeoPhotonics also reported in early May, but didn't make any waves then.
